

## Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation

**Short Title:** Effect of Apixaban on endogenous fibrinolysis

Nikolaos Spinthakis MB BS, MRCP<sup>1,2</sup>, Ying Gue MB BS, MRCP<sup>1,2</sup>, Mohamed Farag MB, BS, PhD<sup>1,2</sup>, Manivannan Srinivasan MB BS, MD, FRCP<sup>2</sup>, David Wellsted PhD<sup>1</sup>, Deepa RJ Arachchillage MD<sup>3,4</sup>, Gregory Y.H. Lip MD, FRCP<sup>5\*</sup>, Diana A Gorog MD, PhD, FRCP<sup>1,2,6\*</sup>

Word count 4550 (inc. references)

1. Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom
2. Department of Cardiology, East and North Hertfordshire NHS Trust, Hertfordshire, United Kingdom
3. Royal Brompton Hospital, London, United Kingdom
4. Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom
5. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
6. National Heart & Lung Institute, Imperial College, London, United Kingdom

[\*joint senior authors]

### Correspondence:

Prof. Diana A Gorog MB BS, MD, PhD, FRCP  
National Heart and Lung Institute  
Dovehouse Street  
London SW3 6LR  
United Kingdom  
Tel +44 (0)207 034 8934; Fax +44 (0)207 0348935  
[d.gorog@imperial.ac.uk](mailto:d.gorog@imperial.ac.uk)

### **Acknowledgement and funding**

This study was supported by a grant from ERISTA (BMS/Pfizer European Thrombosis Investigator Initiated Research Program, BMS protocol number: CV185-622). The investigators acknowledge the support of the U.K. National Institute for Health Research Clinical Research Network (NIHR CRN).

### **Disclosures**

GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

DAG: Related through family to a director in Thromboquest Ltd. but no personal or institutional research sponsorship received from this company, and instrument and consumables purchased through normal commercial transactions. Speaker/honoraria from Bayer, BMS, Abbott. DRJA received sponsorships to attend national and international meetings from Bayer, Boehringer Ingelheim.

Other co-authors have no conflicts to declare.

## ABSTRACT

*Background* Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown.

*Objective* Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular AF (NVAf).

*Methods* In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAf patients (n=180) taking aspirin, warfarin or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban (n=80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and Thromboelastography (TEG).

*Results* Endogenous fibrinolysis (measured by GTT lysis time [LT]) was shorter on apixaban compared to warfarin or aspirin (median 1850[IQR 1591-2300] vs. 2758[2014-3502] vs. 2135[1752-2463] sec,  $p<0.0001$ ). Among TEG indices, a small but significant difference in clot lysis time (CLT) was observed (apixaban 60.0[45.0-61.0] vs. warfarin 61.0[57.0-62.0] vs. aspirin 61.0[59.0-61.0] min,  $p=0.036$ ). Apixaban improved endogenous fibrinolysis measured using the GTT (LT pre-treatment 2204[1779-2738] vs. on-treatment 1882[1607-2374] sec,  $p=0.0003$ ), but not by using TEG. Change in LT ( $\Delta$ LT) with apixaban correlated with baseline LT ( $r=0.77$ ,  $p<0.0001$ ). There was weak correlation between  $\Delta$ LT and  $\Delta$ CLT in response to apixaban ( $r=0.28$ ,  $p=0.02$ ) and between on-apixaban LT and CLT ( $r=0.25$ ,  $p=0.022$ ).

*Conclusions* Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer

additional thrombotic risk reduction in NVAf patients with impaired fibrinolysis, compared to warfarin, merits further study.

Word count 248

**Key words:**

Endogenous fibrinolysis, thrombosis, apixaban, atrial fibrillation, NOAC.

**Abbreviations:**

AF atrial fibrillation

CLT clot lysis time

CV coefficient of variation

GTT Global Thrombosis Test

LT lysis time

NOAC non-vitamin K antagonist oral anticoagulants

NVAF non-valvular atrial fibrillation

OT occlusion time

TEG Thromboelastography

VKA vitamin K antagonist

## Introduction

Spontaneous fibrinolysis is an important defence mechanism against downstream infarction following occlusive arterial thrombosis. In patients with acute stroke, spontaneous arterial recanalization is observed in 17–24% of patients and is strongly related to improved functional outcomes. Importantly, *ex vivo* endogenous fibrinolysis has been shown to be significantly impaired in patients with stroke compared to normal volunteers<sup>1</sup>. Impaired endogenous fibrinolysis has also been shown to be marker of recurrent thrombotic risk in patients with acute coronary syndrome<sup>2</sup> and end-stage renal failure<sup>3</sup>.

Patients with atrial fibrillation (AF) frequently exhibit impaired endogenous fibrinolysis and preliminary data indicate that this state improves after successful restoration of sinus rhythm with radiofrequency ablation<sup>4</sup>. A review of the importance of endogenous fibrinolysis in determining clinical outcomes concluded that global assays, assessing proaggregatory and fibrinolytic pathways, could aid in identifying impaired fibrinolysis as a potential target for pharmacological modulation<sup>3</sup>.

Currently, there is no available oral pharmacotherapy to favourably modulate fibrinolytic status where this is impaired. Beside the use of plasminogen activators to achieve acute thrombolysis in the setting of acute myocardial infarction and stroke, pharmacological options to manipulate the fibrinolytic state are limited. Our preliminary data indicate that the non-vitamin K antagonist oral anticoagulants (NOACs) may enhance endogenous fibrinolysis in patients with AF, with significant effect observed only with apixaban<sup>4</sup>. In our pilot data in 20 patients, apixaban enhanced endogenous fibrinolysis, evidenced by a significant reduction in endogenous fibrinolysis time. However, it is noteworthy that with all NOACs, there was a

trend to favourably enhancing endogenous fibrinolysis and perhaps if the sample size had been sufficiently large, a significant effect may have been observed. Neither warfarin, nor aspirin or clopidogrel, have been shown to enhance endogenous fibrinolysis.

Nevertheless, the impact of pharmacotherapy on the effectiveness of the spontaneous endogenous fibrinolytic pathway has been difficult to measure, due to lack of available techniques. Factorial assays such as plasminogen activator inhibitor 1, tissue plasminogen activator and thrombin activatable fibrinolysis inhibitor cannot provide a reflection of the *overall* state of endogenous fibrinolysis<sup>3</sup>. There are currently 2 point-of-care techniques that provide a global assessment of thrombus formation and fibrinolysis, namely thromboelastography (TEG or ROTEM), which uses citrated or whole blood, and the Global Thrombosis Test (GTT), using non-anticoagulated blood. The determinants of the results of these global tests of fibrinolysis are the thrombus properties (clot strength, determined by the thickness, density, and pore size of fibrin strands) and the rate of fibrinolysis.

We hypothesised that there was beneficial effect of apixaban on endogenous fibrinolysis in patients with NVAf. To test this hypothesis, we performed a cross sectional study of NVAf patients treated with apixaban, warfarin or aspirin. Second, we assessed the impact of initiating apixaban.

## Methods

We conducted a prospective, observational (non-randomised) study in 200 stable out-patients with non-valvular atrial fibrillation (NVAF), approved by the National Research Ethics Service and the UK Health Research Authority (ClinicalTrials.gov identifier: NCT03199521). All subjects gave written informed consent and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

The study comprised 2 arms; a longitudinal arm (n=80) and a cross-sectional arm (n=180), with 60 patients on apixaban taking part in both. In the prospective longitudinal study, 80 patients with newly diagnosed NVAF were recruited, who were scheduled to start anticoagulation with apixaban for thromboprophylaxis of stroke and systemic embolism and who were studied before and during apixaban treatment. In the cross-sectional study, 180 patients with known NVAF already established on treatment with one of aspirin (n=60), warfarin (n=60) or apixaban (n=60) for thromboprophylaxis of stroke and systemic embolism, were studied in an observational study, where drug allocation was by physician choice, and not randomised.

The following exclusion criteria were applied: age <18 years; significant hepatic or renal impairment likely to cause a bleeding diathesis; patients taking antiplatelet or anticoagulant therapy (except for patients taking part in the cross-sectional study), systemic steroids or immunosuppression; known active malignancy; bleeding diathesis; blood dyscrasia (platelets <70 x10<sup>9</sup>/L, haemoglobin <80g/L, international normalized ratio [INR] >1.4; activated partial thromboplastin time [aPTT] more than twice upper limit of normal; leukocyte count <3.5x10<sup>9</sup>/L, neutrophil count <1x10<sup>9</sup>/L); active alcohol or substance abuse; those involved in



another investigational trial of a medicine or medical device; those unable or unwilling to provide consent.

### *Antithrombotic therapy*

The choice of oral antithrombotic therapy was decided by the clinical care team. Apixaban was given at a dose of 5mg b.i.d. (or 2.5 mg b.i.d. in patients with two or more of the following: age  $\geq$ 80 years, weight  $\leq$ 60 kg, serum creatinine  $\geq$ 133  $\mu$ mol/L). In the longitudinal study, blood samples were taken before (i.e. non-anticoagulated) and after patients were established on uninterrupted apixaban treatment for at least 4 weeks. For the cross-sectional study, blood samples were obtained after patients had been established on treatment for at least 4 weeks. Patients taking warfarin were tested after at least three previous consecutive INR readings within the therapeutic range (2.0-3.0).

### *Blood sampling*

Venous blood samples were obtained from an antecubital vein using an 18-G butterfly cannula and a two-syringe technique. The first 5 ml was used for routine blood tests and the second 10 ml used for assessment of thrombotic status and apixaban levels measured using drug-specific calibrators (anti-Xa [FXa] level). Blood samples were taken 4-6 hours after the last dose of apixaban. Fasting was not required.

### *Assessment of thrombotic status including endogenous fibrinolysis*

#### Global Thrombosis Test

Thrombotic status was assessed using the point-of-care Global Thrombosis Test (GTT, Thromboquest Ltd., London, UK), which assesses overall thrombotic status, including

platelet reactivity, coagulation and endogenous (spontaneous) thrombolysis. ~~which assesses both platelet reactivity to high shear stress and endogenous fibrinolysis<sup>2</sup>~~. The test was performed on native, non-anticoagulated whole blood within 15 s of withdrawal. The instrument assesses firstly the time taken to form an occlusive thrombus under high shear, which is a marker of platelet reactivity (occlusion time, OT). Shorter occlusion time represents enhanced platelet reactivity. Following the arrest of flow due to the formation of an occlusive platelet thrombus crosslinked by fibrin strands. Following a short stabilisation period, the instrument records the time required to dissolve the thrombus formed in the first phase, through endogenous fibrinolysis, which manifests in restart of flow (lysis time, LT). Longer lysis times represent less effective endogenous fibrinolysis. In addition, the GTT measures thrombus stability by measuring the number of rebleeds (number of drops, D) after OT until the complete occlusion and final arrest of flow. The intra-assay and inter-assay coefficients of variation (CV) for OT and LT were assessed in 10 subjects on repeated sampling and also running samples in parallel.

### Thromboelastography

Venous blood was also assessed with thromboelastography (TEG 5000 Hemostasis Analyser System, Haemonetics, Watford, UK). Two tests were performed in parallel for each patient, one using non-citrated whole blood tested immediately after withdrawal and one using non-citrated whole blood with the addition of kaolin activator after four minutes, according to the manufacturer's instructions. The TEG assesses platelet-independent clot formation, fibrinogen contribution to clot integrity (R, K, A, MA, TMA) as well as the primary fibrinolytic potential of the clot (LY30, LY60, CLT) (Table 3). The intra-assay and inter-assay coefficients of variation (CV) for all TEG parameters were assessed in 10 subjects on

repeated sampling and running samples in parallel for the whole blood alone and with kaolin activator.

### **Apixaban (anti-FXa) levels**

In patients taking apixaban, samples were taken for apixaban level at the same time as blood draw for thrombotic status assessment. Apixaban level was measured using HemosIL Liquid Heparin kit (Werfen UK, Birchwood, Warrington, Cheshire, UK) on ACL TOP500 analyser using drug-specific callibrators. Based on population pharmacokinetics studies on patients taking apixaban 5mg b.i.d. for stroke prevention in NVAf, peak and trough levels of apixaban (measured as anti-FXa levels) have been reported as 171ng/ml (91-321) and 103ng/ml (41-230) respectively<sup>5</sup>. Anti-FXa levels were assessed by an independent investigator blinded to GTT and TEG results.

### **Study endpoints**

The primary endpoint was the change in thrombotic status, in particular endogenous fibrinolysis, in response to apixaban in the longitudinal study. The secondary endpoint was a comparison of endogenous fibrinolysis in patients established on different antithrombotic treatments (apixaban, warfarin, aspirin) in the cross-sectional study.

### **Sample size and statistical analysis**

Results from our pilot study<sup>4</sup> showed a 24% relative reduction in endogenous fibrinolysis time with apixaban with a medium effect size ( $r=0.4$ ,  $z=2.763$ ,  $p=0.006$ ). Using a two-tailed t test, we calculated that a sample size of 78 patients would be required to detect a 24% relative reduction with 90% power based on an effect size of 0.4 and  $\alpha=0.05$  (longitudinal study). For the cross-sectional study, it was assumed that endogenous fibrinolysis in patients

taking warfarin and aspirin would be similar, based on our earlier pilot showing no change in endogenous fibrinolysis in response to warfarin (8). Assuming a one-tailed independent group comparison and an effect size of 0.4, a total of 180 patients were required to give  $\alpha=0.05$  to achieve 80% power.

Data are presented as mean $\pm$ standard deviation when normally distributed, or as median (interquartile range), when non-normally distributed. Dichotomous variables were compared using chi-square test. Paired comparison between groups was evaluated with paired t-test and Wilcoxon ranked sum test. The analysis of variance (ANOVA) or Kruskal-Wallis test were used to assess differences between groups. To investigate the relationship between the change in fibrinolysis in response to apixaban and baseline characteristics, univariate and multivariate regression models were used. All variables were analysed using univariate regression; clinically relevant parameters and those shown to be significant ( $p\leq 0.05$ ) were entered into the multivariate model. In a post hoc analysis, the model's assumptions were tested and the residuals were normally distributed. Regression models were used to illustrate the linear prediction between change in LT ( $\Delta$  LT) and baseline LT. Correlations were analysed using Pearson's and Spearman's methods. Analyses were performed with Stata version 15.1 (StataCorp, College Station, TX, USA).

## **Results**

Between June 2017 and May 2018, 270 patients were screened and 200 patients recruited. Clinical characteristics of patients in the longitudinal study are presented in Table 1 and those in the cross-sectional study in Table 2. For the GTT, the intra-assay CV for OT was 6% and

for LT 8%, and the inter-assay CV was 7% for OT and 9% for LT. The average intra-assay CV for TEG was 22% using native blood and 20% for native blood with kaolin.

### ***Effect of apixaban on thrombotic status including endogenous fibrinolysis***

Distributions of OT and LT pre- and during apixaban treatment are shown in Figure 1. Compared to baseline, apixaban significantly prolonged OT [361±112 vs. 463±124 sec,  $p<0.0001$ ]. The number of drops (D) did not change in response to apixaban treatment [2.5±1.7 vs. 3.1±1.6,  $p=0.173$ ]. There was moderate inverse correlation between the change in OT in response to apixaban ( $\Delta$ OT) and baseline OT ( $r=-0.4$ ,  $p=0.0002$ ).

Compared to baseline, LT on apixaban was significantly shorter (2204[1779-2738] vs. 1882[1607-2374] sec,  $p=0.0003$ ). There was no correlation between baseline OT and baseline LT ( $p=0.740$ ) or between on-treatment OT and on-treatment LT ( $p=0.241$ ).

Apixaban did not alter TEG indices, except for a small reduction in the rate of clot formation with kaolin (68.4° vs. 67°,  $p=0.026$ ) (Tables 3 and 4).

Baseline OT and LT did not correlate with any of the baseline TEG indices with or without kaolin. In particular, baseline fibrinolysis assessment (LT) with the GTT did not correlate with any of the baseline TEG indices of fibrinolysis (LY30, LY60 and CLT). On-treatment OT did not correlate with any on-treatment TEG indices. There was a significant correlation between  $\Delta$ OT and the change in reaction time (R) with kaolin in response to apixaban ( $r=0.54$ ,  $p<0.0001$ ). There was a weak correlation between on-treatment LT in GTT correlated with clot lysis time (CLT) in the TEG ( $r=0.25$ ,  $p=0.022$ ). There was weak correlation between  $\Delta$ LT and the change in kaolin CLT ( $\Delta$ CLT) in response to apixaban ( $r=0.28$ ,  $p=0.02$ ).

### *Magnitude of effect of apixaban in relation to baseline fibrinolysis*

The change in LT in response to apixaban ( $\Delta$ LT) correlated closely with baseline LT ( $r=0.77$ ,  $p<0.0001$ ). The magnitude of effect of apixaban on reducing LT was greatest in those with the longest LT at baseline (Figure 2). Patients on apixaban were grouped into quartiles based on baseline LT to assess the magnitude of change in LT with apixaban (Table 1). The  $\Delta$ LT between the four groups was significantly different ( $p<0.0001$ ).

### *Cross-sectional comparisons of apixaban, warfarin and aspirin*

Measures of thrombotic status assessed with GTT and TEG are shown in Table 5. LT was significantly lower in patients taking apixaban than other medications. From the TEG indices, only native CLT was significantly lower in the apixaban group compared to patients on warfarin and aspirin. Multivariable regression models were applied to account for baseline differences in the three groups. After accounting for these variables (Table 2) both OT and LT remained significantly different between the apixaban and the warfarin arms ( $p<0.0001$ ).

### *Relationship of thrombotic effect to apixaban levels*

Apixaban levels in patients taking 5mg b.i.d. was  $C_{max}$  152.9 ng/ml (32.9-317.9 ng/ml), and in patients taking the 2.5mg b.i.d. dose was  $C_{max}$  125.85 ng/ml (40.6-344.6 ng/ml). Apixaban levels correlated weakly with OT on apixaban ( $r=0.27$ ,  $p=0.022$ ) but not with LT.

There were no significant relationships between apixaban levels and TEG parameters.

## DISCUSSION

In this study, our principal findings are as follow: (i) Apixaban significantly improved endogenous fibrinolysis, and the effect of apixaban was greatest in those patients with the longest lysis time at baseline; and (ii) In comparison to patients on warfarin or aspirin, patients taking apixaban exhibited more rapid (more effective) endogenous fibrinolysis.

These observations may have clinical relevance, given that effectiveness of endogenous fibrinolysis is an important determinant of the clinical outcome of a thrombotic stimulus. Whether apixaban may confer additional thrombotic risk reduction in NVAf patients who have impaired fibrinolysis, compared to warfarin, requires further study. Importantly, the finding that apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin does not mean that apixaban by itself exhibits a more favourable fibrinolysis profile as compared to aspirin and warfarin.

In our current study, 23% of patients with NVAf had significantly prolonged lysis time before the start of anticoagulation (defined as baseline  $LT > 3000$  sec, based on prior data)<sup>3</sup>. Such impaired endogenous fibrinolysis in patients with acute coronary syndromes has been associated with increased risk of cardiovascular death and recurrent MI<sup>2,3,5</sup>. Dual antiplatelet therapy post-ACS did not appear to reduce LT. The average 15% reduction in fibrinolysis time with apixaban seen here is potentially clinically significant, but even greater effect, up to 48% reduction in LT was seen in those with the most impaired fibrinolysis at baseline. If apixaban were to exert similar reduction in LT in patients with ACS, as that observed here in NVAf, that would be expected to reduce the risk of MACE in those with prolonged LT at baseline. Our observations suggest that further study in controlled trials could investigate

whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin.

The effect of improving fibrinolytic status with apixaban appears not to be simply an anticoagulant effect, since patients on apixaban had more rapid fibrinolysis than patients therapeutically anticoagulated with warfarin, and there was no relation between apixaban levels and LT. Apixaban levels in our study were similar to those previously reported<sup>5</sup> and are known to correlate closely with anti-FXa activity. In the ARISTOTLE trial, apixaban was as effective as warfarin in reducing the risk of ischaemic stroke and systemic embolism in NVAF, whilst the AVERROES study showed that apixaban was superior to aspirin<sup>6</sup>. Both ARISTOTLE and AVERROES suggest a greater benefit of apixaban, compared to warfarin, in reducing ischaemic stroke and systemic embolism in patients with CHADS<sub>2</sub> score  $\geq 3$  than in patients with lower CHADS<sub>2</sub> scores, suggesting apixaban may have additional advantages in the highest risk patients. Although in the ARISTOTLE trial comparing apixaban with warfarin in NVAF, the secondary endpoint of combined ischaemic or uncertain type (not clearly haemorrhagic or ischemic) stroke was non-significantly different with both anticoagulants<sup>7</sup>, a subgroup analysis of patients with previous stroke or TIA showed the rate of stroke or systemic embolism was significantly lower with apixaban than with warfarin, suggesting that the absolute benefits of apixaban might be even greater in high-risk patients<sup>8</sup>. In the largest real-world retrospective analysis of ~77,000 patients with NVAF, apixaban use was associated with significantly lower risk of stroke and systemic embolism than warfarin<sup>9</sup>.

Apixaban is a direct inhibitor of free and clot- or prothrombinase-bound FXa and, thereby, prevents thrombin generation. Thrombin is not only a key protein in fibrin clot formation, but also the most potent activator of platelet aggregation *in vivo*<sup>10</sup> and an important determinant



of the strength and stability of the fibrin clot and its resistance to fibrinolysis<sup>11</sup>. Apart from reduced thrombin generation, FXa inhibition with apixaban might also impact platelet haemostasis by blocking the direct effects of FXa via protease activator receptor signalling<sup>10</sup>. Nevertheless, studies assessing the effect of FX inhibition on platelet reactivity are few, but appear to show consistency in reduction of tissue-factor/platelet-dependent thrombin generation and thrombus formation. Blood spiked with rivaroxaban *ex vivo* showed reduced platelet aggregation induced by tissue factor and to a lesser extent induced by thrombin<sup>12,13</sup>. Even at the very low dose of 2.5 mg b.i.d., rivaroxaban reduced platelet-dependent thrombin generation and coagulation-dependent thrombus-formation in patients treated with aspirin plus P2Y<sub>12</sub> inhibitor, whereas pure platelet-dependent thrombus formation was not affected<sup>14</sup>. Indeed, FXa inhibition appears to have no significant effect on platelets<sup>14</sup> including in response to adenosine diphosphate, collagen, thrombin receptor-activating peptide or arachidonic acid<sup>15</sup>. Apixaban may therefore favourably enhance endogenous fibrinolysis through reduction in platelet-dependent and non-platelet dependent thrombin generation, which directly impact on the structure and stability of the thrombus and its resistance to fibrinolysis.

The benefit of apixaban on endogenous fibrinolysis was only observed with the Global Thrombosis Test and not with TEG. The fundamental difference between these techniques is that the GTT employs high shear to stimulate thrombus formation resulting in platelet activation and thrombin generation, whereas TEG is a haemostatic assay that measures the global viscoelastic properties of whole blood clot formation under low shear. This results in significant differences in the clot formed and therefore also in what the “lysis” assays measure. The GTT assesses the lysis and stability of a platelet thrombus, whereas in the TEG it reflects clot lysis. The GTT is particularly well-adapted to investigate the role of thrombin

inhibitors such as NOACs, primarily because thrombin generation from shear-activated platelets and fibrin stabilization of the initial platelet aggregates play a major role in determining the measured occlusion time<sup>3</sup>, whereas platelet-dependent thrombin generation is much less likely at the low shear rates in the TEG.

Nevertheless, the effect of NOACs on TEG parameters is contentious. Whilst some small studies reported that apixaban had minimal effect on TEG parameters, and that for the patients on apixaban, mean R value was within reference range representative of a normal population<sup>16</sup>, others have shown that spiking of blood with apixaban *in vitro* increased R time and time to maximal thrombus growth and coagulation<sup>17</sup>, prolonged clotting time and time to maximum velocity<sup>18</sup>. In the largest study assessing patients with NVAF with TEG, patients taking NOAC developed clot that was quicker to lyse than patients taking warfarin, and the rate of clot dissolution was faster in those on apixaban than in rivaroxaban, with 11 of 16 TEG indices showing a difference between those on aspirin, warfarin or a NOAC<sup>19</sup>.

### *Clinical implications*

Our finding that that apixaban significantly improves endogenous fibrinolysis, particularly in patients with the longest lysis time at baseline, is significant and may be clinically important. The current data indicate that apixaban may have additional advantages over VKA or aspirin in patients with impaired endogenous fibrinolysis, although since we did not assess patients pre- and post-VKA or aspirin, we cannot be sure of the relative effects of apixaban on fibrinolysis compared to VKA or aspirin.

Our findings support the signals from clinical trials, showing that apixaban (rather than VKA or aspirin) may have additional advantages in high risk patients. Our data suggest that patients with impaired fibrinolysis may benefit more from apixaban to improve fibrinolysis, than

warfarin. Future studies are required to confirm whether patients with NVAF and impaired fibrinolysis are at increased risk of ischaemic stroke and systemic embolism, than those with effective fibrinolysis. If this is confirmed in large prospective studies, then patients with NVAF and impaired fibrinolysis may gain additional benefits from treatment with apixaban to favourably modulate endogenous fibrinolysis, than from VKA or aspirin.

~~Whether enhancing endogenous fibrinolysis with apixaban when this is impaired in patients with NVAF or even in acute coronary syndromes, can translate into a reduction in ischaemic events, and whether patients with prolonged LT derive greater benefit from apixaban than warfarin or other NOAC, requires further study.~~

### *Limitations*

The main limitations of our study are the non-randomized, observational study design and the relatively small number of participants. The baseline LT in patients subsequently treated with apixaban was not uniform and therefore a greater effect of apixaban on LT may have been observed had we included more patients with impaired fibrinolysis at baseline. In the cross-sectional study, there were differences in clinical characteristics between the groups. Since fibrinolysis was not assessed before aspirin or warfarin treatment, we do not know the absolute magnitude of effect of these drugs on fibrinolysis, which may confound conclusion drawn about the observed shorter LT in patients on apixaban than on warfarin or aspirin. However, in contemporary clinical practice, few patients in the U.K. with NVAF are being started on VKA and therefore it would not have been logistically easy to compare patients pre- and post-VKA. Furthermore, whilst compliance was assessed in the apixaban and warfarin arms, it was not assessed in patients taking aspirin.

In conclusion, apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAf patients with impaired fibrinolysis, compared to warfarin, merits further study.

## References

1. Taomoto K, Ohnishi H, Kuga Y, Nakashima K, Ichioka T, Kodama Y, et al. Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test. *Pathophysiol Haemost Thromb* 2010;37:43–48.
2. Farag M, Spinhakis N, Gue YX, Srinivasan M, Sullivan K, Wellsted D, et al. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. *Eur Heart J* 2019;40:295–305.
3. Okafor ON, Gorog DA. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. *J Am Coll Cardiol* 2015;65:1683–1699.
4. Farag M, Niespialowska-Steuden M, Okafor O, Artman B, Srinivasan M, Khan A, et al. Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. *Platelets* 2016;27:687–693.
5. Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. *Thromb Haemost* 2018;118:437–450.
6. Connolly S, Eikelboom J, Joyner C, Diener HC, Hart R, Golytsin S et al. Apixaban in patients with atrial fibrillation. *New Engl J Med* 2011;364:806-817.

7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *New Engl J Med* 2011;365:981–992.
8. Easton J, Lopes RD, Bahit M, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. *The Lancet Neurology* 2012;11:503–511.
9. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’ clinical practice. A propensity-matched analysis of 76,940 patients. *Thromb Haemost* 2017;117:1072–1082.
10. Pasma J, Posthuma J, Ronk H. Coagulation and non-coagulation effects of thrombin. *J Thromb Haemostasis* 2016;14:1908–1916.
11. Wolberg AS. Thrombin generation and fibrin clot structure. *Blood Reviews* 2007;21:131–142.
12. Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, et al. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. *Blood Coagul Fibrinolysis* 2016;27:882–885.

13. Perzborn E, Heitmeier S, Laux V. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. *J Cardiovasc Pharmacol Therapeutics* 2015;20:554–562.
14. Borst O, Münzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, et al. Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. *Blood Advances* 2018;2:715–730.
15. Steppich B, Dobler F, Brendel L, Hessling G, Braun S, Steinsiek A, et al. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. *J Thromb Thrombolysis* 2017;43:490–497.
16. Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. *J Thromb Thrombolysis* 2017;43:437–445.
17. Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. *Arch Pathol Lab Med* 2015;139:665–673.
18. Adelman D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. *Thromb Res* 2014;134:918–923.
19. Lau Y, Xiong Q, Shantsila E, Lip GY, Blann AD. Effects of non-vitamin K antagonist

oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. *J Thromb Thrombolysis* 2016;42:535-44.



**Table 1. Baseline clinical characteristics of patients in longitudinal study**

	<b>Whole group</b>	<b>Baseline</b>	<b>Baseline</b>	<b>Baseline</b>	<b>Baseline</b>	<b>P</b>
		<b>LT</b>	<b>LT</b>	<b>LT</b>	<b>LT</b>	<b>Value</b>
		<b>0-1500</b>	<b>1501-3000</b>	<b>3001-4500</b>	<b>4501-6000</b>	
	<b>(n=80)</b>	<b>(n=9)</b>	<b>(n=53)</b>	<b>(n=11)</b>	<b>(n=7)</b>	
<b>Age (yrs)</b>	69.5±13.6	70.2±11.7	69.0±15.0	67.3±11.6	76.0±7.0	0.675
<b>Male</b>	43(54)	2(22)	33(62)	6(55)	2(29)	0.074
<b>Weight (kg)</b>	83.28±26.64	67.57±19.61	83.39±25.78	95.57±35.46	83.31±18.11	0.211
<b>Height (cm)</b>	169.00±14.21	163.77±9.47	172.00±11.35	160.90±25.79	165.71±7.86	0.085
<b>BMI</b>	27.93±6.50	24.80±5.25	27.68±6.73	30.31±5.96	30.00±6.01	0.819
<b>Current smoker</b>	5(6.3)	1(11)	3(5.6)	1(9)	0(0)	0.798
<b>AF type</b>						
<b>Paroxysmal</b>	71(88.8)	7(78)	47(89)	10(90)	7(100)	0.567
<b>Persistent</b>	9(11.2)	2(22)	6(11)	1(10)	0(0)	0.512
<b>Hypertension</b>	48(60)	4(44)	30(56)	9(82)	5(71)	0.293
<b>Diabetes mellitus</b>	11(13.8)	2(22)	7(13)	2(18)	0(0)	0.603
<b>Hyperlipidemia</b>	29(36.3)	3(33)	20(38)	5(45)	1(14)	0.583
<b>Prior CAD</b>	5(6.25)	0(0)	4(7.5)	1(9)	0(0)	0.712
<b>Prior MI</b>	2(2.5)	0(0)	1(2)	1(9)	0(0)	0.484
<b>Prior PCI</b>	2(2.5)	0(0)	2(3.7)	0(0)	0(0)	0.790
<b>Renal impairment</b>	3(3.8)	1(11)	2(3.7)	0(0)	0(0)	0.562
<b>Prior major bleeding</b>	2(2.5)	0(0)	2(3.75)	0(0)	0(0)	0.790
<b>Prior CVA</b>	3(3.8)	0(0)	3(5.5)	0(0)	0(0)	0.662
<b>LV impairment</b>						
<b>None</b>	72(90)	7(77)	47(89)	11(100)	9(100)	0.308
<b>Mild</b>	5(6)	1(11)	3(5.5)	0(0)	0(0)	0.636
<b>Moderate</b>	2(2.5)	1(11)	1(1.8)	0(0)	0(0)	0.350
<b>Severe</b>	1(1.5)	0(0)	2(3.7)	0(0)	0(0)	0.790
<b>CHA<sub>2</sub>DS<sub>2</sub>VASC score</b>	3[1-4]	3[2-3]	2[1-4]	3[2-3]	3[2-3]	0.193

<b>HASBLED score</b>	1[1-1]	1[1-1]	1[1-1]	1[0-1]	1[1-2]	0.128
<b>Concomitant medication</b>						
<b>Statin</b>	29(36)	4(44)	20(38)	4(36)	1(14)	0.621
<b>Beta blocker</b>	21(26)	1(11)	14(26)	5(45)	1(14)	0.298
<b>CCB blocker</b>	23(28.75)	2(22)	12(23)	5(45)	4(57)	0.144
<b>PPI</b>	17(21.25)	2(22)	11(21)	2(18)	2(29)	0.960
<b>Metformin</b>	6(7.5)	1(11)	4(7.5)	1(9)	0(0)	0.855
<b>Baseline blood tests</b>						
<b>Haemoglobin (g/L)</b>	138±19	127±18	139±20	144±9	134±19	0.118
<b>Haematocrit (%)</b>	41±5	38±5	41±5	43±3	40±7	0.151
<b>Platelet count</b>	257±85	296±76	248±85	249±28	281±141	0.259
<b>(x10<sup>9</sup>/L)</b>						
<b>White cell count</b>	8.7±2.7	7.7±1.8	8.8±2.4	8.4±3.2	9.1±5.6	0.583
<b>(x10<sup>9</sup>/L)</b>						
<b>eGFR</b>	72±16	74±21	71±16	77±14	65±11	0.261
<b>Fibrinogen (g/L)</b>	4.5±1.5	3.6±0.5	4.4±1.5	4.8±0.9	5.8±1.7	0.122
<b>PT (sec)</b>	12.0±1.4	11.5±1.3	12.0±1.4	12.1±1.7	11.5±0.9	0.748
<b>aPTT (sec)</b>	28.6±3.3	28.6±4.0	28.0±2.2	31.0±6.2	29.2±3.0	0.411
<b>CRP (mg/L)</b>	4.8±6.6	2.3±2.2	5.4±7.7	3.2±2.8	7±5	0.182
<b>OT at baseline (sec)</b>	361±112	377±126	360±110	376±109	324±130	0.740
<b>LT at baseline (sec)</b>	2204	1425	2114	3427	5166	<b>&lt;0.001</b>
	[1779-2738]	[1350-1454]	[1800-2347]	[3099-3667]	[4843-6000]	
<b>OT on treatment (sec)</b>	463±124	501±98.4	452±118	542±151	376±88	<b>0.038</b>
<b>LT on treatment (sec)</b>	1882	1367	1866	2322	2707	<b>&lt;0.001</b>
	[1607-2374]	[1206-1607]	[1631-2312]	[1975-3345]	[1710-3285]	

Values are mean±SD or median[IQR] and n(%).

BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe <35% ejection fraction.

CHA<sub>2</sub>DS<sub>2</sub>VASc score in AF and HAS-BLED bleeding risk, please see references (35, 36).

Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 40-52% in males and 36-47% in females; platelet count 150-400 x10<sup>9</sup>/L; white cell count 4-11 x10<sup>9</sup>/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-reactive protein 0-5 mg/L.

**Table 2. Baseline clinical characteristics of patients in cross-sectional study**

	<b>Whole group</b>	<b>Apixaban</b>	<b>Warfarin</b>	<b>Aspirin</b>	<b>P Value</b>
	<b>(n=180)</b>	<b>(n=60)</b>	<b>(n=60)</b>	<b>(n=60)</b>	
<b>Age (yrs)</b>	73.8±12.1	69.6±13.4	74.6±9.7	77.1±12.0	0.248
<b>Male</b>	105(58)	33(55)	35(58)	37(62)	0.636
<b>Weight (kg)</b>	82.37±21.22	83.70±27.15	83.62±18.01	79.80±17.16	0.573
<b>Height (cm)</b>	169.48±11.87	168.45±15.68	171.11±8.83	168.88±9.97	0.567
<b>BMI</b>	28.00±5.60	28.25±7.08	28.13±5.03	27.60±4.35	0.652
<b>Current smoker</b>	11(6)	5(8)	4(7)	2(3)	0.598
<b>AF type</b>					
<b>Paroxysmal</b>	138(76)	54(90)	35(60)	48(80)	<b>0.001</b>
<b>Persistent</b>	28(16)	6(10)	12(20)	10(17)	0.115
<b>Hypertension</b>	122(68)	37(62)	42(70)	43(70)	0.454
<b>Diabetes mellitus</b>	33(18)	9(15)	12(20)	12(20)	0.716
<b>Hyperlipidemia</b>	99(55)	26(43)	31(52)	42(70)	<b>0.011</b>
<b>Prior CAD</b>	44(24)	3(5)	20(33)	21(35)	<b>&lt;0.001</b>
<b>Prior MI</b>	20(11)	2(3)	10(17)	8(13)	0.054
<b>Prior PCI</b>	15(8)	2(3)	9(15)	4(6)	0.059
<b>Renal impairment</b>	18(10)	2(3)	7(12)	9(15)	0.090
<b>Prior major bleeding</b>	7(4)	2(3)	5(8)	0(0)	0.059
<b>Prior CVA</b>	25(14)	3(5)	11(18)	11(18)	0.051
<b>Prior LV impairment</b>					
<b>None</b>	150(83)	54(90)	47(78)	49(82)	0.090
<b>Mild</b>	15(8)	3(5)	6(10)	6(10)	0.253
<b>Moderate</b>	9(5)	1(2)	6(10)	2(3)	0.147
<b>Severe</b>	6(4)	2(3)	1(2)	3(5)	1.000
<b>CHA<sub>2</sub>DS<sub>2</sub>VASC score</b>	3[2-4]	3[1-4]	4[2-5]	4[3-5]	0.945
<b>HASBLED score</b>	1[1-2]	1[1-1]	1[1-2]	1[1-2]	0.388
<b>Concomitant medication</b>					

<b>Statin</b>	107(59)	25(42)	40(66)	42(70)	<b>0.003</b>
<b>Beta blocker</b>	92(51)	15(25)	11(18)	15(25)	<b>&lt;0.001</b>
<b>CCB</b>	44(24)	18(30)	11(18)	15(25)	0.329
<b>PPI</b>	68(38)	13(22)	26(43)	29(48)	<b>0.006</b>
<b>Metformin</b>	19(11)	5(8)	7(12)	7(12)	0.790
<b>Baseline blood tests</b>					
<b>Haemoglobin (g/L)</b>	134±17	138±18	132±15	133±16	0.428
<b>Haematocrit (%)</b>	40±5	41±5	40±4	40±4	0.743
<b>Platelet count (x10<sup>9</sup>/L)</b>	227±72	235±55	215±85	229±72	0.052
<b>White cell count (x10<sup>9</sup>/L)</b>	7.6±2.0	7.9±2.1	7.1±1.9	7.7±2.0	0.093
<b>eGFR</b>	67±16	70±16	66±16	65±17	0.139
<b>Fibrinogen (g/L)</b>	4.5±1.1	4.4±1.4	4.5±1.0	4.5±0.9	0.402
<b>PT (sec)</b>	17.7±9.1	12.0±1.4	29.5±6.7	12.3±2.3	<b>&lt;0.001</b>
<b>aPTT (sec)</b>	32.0±7.3	28.3±3.3	38.8±7.3	29.0±5.4	<b>&lt;0.001</b>
<b>CRP (mg/L)</b>	5.5±10.6	4.7±6.4	4.0±3.6	7.4±16	0.872

Values are mean±SD or median[IQR] and n(%).

BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe <35% ejection fraction.

CHA<sub>2</sub>DS<sub>2</sub>VASc score in AF and HAS-BLED bleeding risk, please see references(35, 36).

Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 40-52% in males and 36-47% in females; platelet count 150-400 x10<sup>9</sup>/L; white cell count 4-

11 x10<sup>9</sup>/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-reactive protein 0-5 mg/L.

**Table 3. TEG indices**

Reaction Time (R) [min]	Measures the time from the start of a sample run until the first significant level of detectable clot formation. R reduces in hypercoagulable conditions
Kinetics (K) [min]	Measures the time from R until a fixed level of clot strength is reached. K is shortened in hypercoagulable conditions.
Angle	Represents the rate of clot formation and reflects fibrinogen activity. Angle relates to K. Both represent the rate of clot formation. Angle is larger in hypercoagulable conditions
Maximum Amplitude (MA) [mm]	Represents whole clot strength and reflects many aspects of clot formation including platelet number and function as well as the fibrin contribution to clot strength. MA is larger by hypercoagulable conditions
LY30 [%]	Represents the percentage of clot which has lysed after 30 minutes of MA
LY60 [%]	Represents the percentage of clot which has lysed after 60 minutes of MA
Time to Maximum Amplitude (TMA) [min]	Measures the time to form maximum clot strength
Clot Lysis Time (CLT) [min]	Measures the time to 2mm amplitude reduction from MA.

**Table 4. Difference in GTT and TEG parameters in response to apixaban**

	<b>Baseline (n=80)</b>	<b>Apixaban (n=80)</b>	<b>P value</b>
<b>OT (sec)</b>	361±112	463±124	<b>&lt;0.0001</b>
<b>LT (sec)</b>	2204[1779-2738]	1882[1607-2374]	<b>0.0003</b>
<b>Reaction Time (R) [min] native</b>	7.8[5.4-11.4]	8.9[6.1-12.2]	0.398
<b>Reaction Time (R) [min] kaolin</b>	4.2[2.6-5.6]	4.8[3.2-6.3]	0.159
<b>Kinetics (K) [min] native</b>	3.6[2.6-5.8]	4.2[3.0-7.2]	0.096
<b>Kinetics (K) [min] kaolin</b>	1.4[1.1-2.2]	1.7[1.4-2.3]	0.113
<b>Angle [°] native</b>	43.0[39.0-47.0]	42.0[38.0-45.0]	0.552
<b>Angle [°] kaolin</b>	68.4[65.0-72.0]	67.0[58.0-70.0]	<b>0.026</b>
<b>Maximum Amplitude (MA) [mm] native</b>	34.5[27.3-48.3]	34.6[29.6-49.8]	0.535
<b>Maximum Amplitude (MA) [mm] kaolin</b>	21.0[17.8-25.0]	23.3[20.0-25.9]	0.068
<b>LY30 [%] native</b>	0.1[0.0-3.1]	0.0[0.0-0.4]	0.276
<b>LY30 [%] kaolin</b>	1.9[0.3-5.4]	0.4[0.0-2.0]	0.066
<b>LY60 [%] native</b>	1.4[0.0-5.8]	0.5[0.0-3.0]	0.405
<b>LY60 [%] kaolin</b>	4.2[1.9-9.9]	2.6[1.0-4.6]	0.067
<b>Time to Maximum Amplitude (TMA) [min] native</b>	34.5[27.3-48.3]	34.6[29.6-49.8]	0.535
<b>Time to Maximum Amplitude (TMA) [min] kaolin</b>	21.0[17.8-25.0]	23.3[20.0-25.9]	0.068
<b>Clot Lysis Time (CLT) [min] native</b>	60.6[59.4-61.5]	60.15[57.7-61.2]	0.155
<b>Clot Lysis Time (CLT) [min] kaolin</b>	60.8[59.5-61.7]	60.8[59.7-61.5]	0.780



**Table 5. Thrombotic parameters in patients taking apixaban, warfarin and aspirin**



OT=occlusion time, LT= lysis time, R=reaction time, K=kinetics, MA=maximal amplitude,

TMA=time to maximal amplitude, CLT=clot lysis time.

	Apixaban (n=60)	Warfarin (n=60)	Aspirin (n=60)	Three group compari son  P value	Apixaban vs. warfarin +aspirin  P value	Apixaban +warfarin vs. aspirin  P value	Apixaba n vs. Warfari n  P value
<b>OT (sec)</b>	463±131	589±154	430±121	0.126	0.054	0.025	<b>&lt;0.0001</b>
<b>LT (sec)</b>	1850	2758	2135	<b>0.0001</b>	<b>&lt;0.0001</b>	0.465	<b>&lt;0.0001</b>
	[1591-2300]	[2014-3502]	[1752-2463]				
<b>R [min] native</b>	8.8[5.7-12.3]	13.0[8.7-17.8]	8.8[6.0-12.2]	<b>0.001</b>	0.059	0.067	<b>0.0007</b>
<b>R [min] kaolin</b>	4.7[3.0-6.8]	6.5[4.9-10.4]	3.0[2.0-5.0]	<b>0.0001</b>	0.843	0.0002	<b>0.006</b>
<b>K [min] native</b>	4.4[3.0-7.2]	5.4[3.4-7.5]	4.0[2.6-6.1]	0.076	0.954	0.0517	0.212
<b>K [min] kaolin</b>	1.7[1.4-2.2]	2.0[1.5-2.7]	1.5[1.2-2.7]	0.152	0.789	0.0367	0.265
<b>Angle [°] native</b>	45.3[30.7-52.1]	33.0[26.2-47.9]	46.0[33.0-59.0]	<b>0.009</b>	0.793	0.011	0.050
<b>Angle [°] kaolin</b>	70.0[57.0-69.0]	61.0[47.0-69.0]	67.3[60.0-72.0]	0.152	0.839	0.084	0.265
<b>MA [mm] native</b>	70.0[64.0-76.0]	69.0[56.0-75.0]	69.0[62.0-75.0]	0.673	0.386	0.830	0.347
<b>MA [mm] kaolin</b>	76.0[72.0-80.0]	75.0[72.0-79.0]	75.0[73.0-79.0]	0.872	0.632	0.819	0.703
<b>LY30 [%] native</b>	0.0[0.0-0.9]	0.0[0.0-1.3]	0.0[0.0-1.1]	0.841	0.810	0.744	0.980
<b>LY30 [%] kaolin</b>	0.4[0.0-2.0]	0.6[0.0-3.9]	1.2[0.3-2.4]	0.872	0.264	0.293	0.520
<b>LY60 [%] native</b>	0.6[0.0-3.1]	0.5[0.0-5.6]	1.3[0.1-4.7]	0.744	0.598	0.542	0.993
<b>LY60 [%] kaolin</b>	2.6[1.0-5.0]	3.0[1.0-9.5]	4.2[2.1-5.9]	0.588	0.321	0.388	0.532
<b>TMA [min] native</b>	35.0[30.0-50.0]	37.0[32.0-49.0]	32.0[26.0-43.0]	0.064	0.874	<b>0.037</b>	0.253
<b>TMA [min] kaolin</b>	24.0[20.0-26.0]	26.0[22.0-30.0]	21.0[16.0-23.0]	<b>0.001</b>	0.798	<b>0.001</b>	0.0511
<b>CLT [min] native</b>	60.0[45.0-61.0]	61.0[57.0-62.0]	61.0[59.0-61.0]	<b>0.036</b>	<b>0.011</b>	0.100	0.055
<b>CLT [min] kaolin</b>	61.0[60.0-62.0]	61.0[60.0-62.0]	60.8[60.4-61.4]	0.998	0.956	0.889	0.883

**Figure 1. Effect of apixaban on occlusion time and lysis time**

(A) Distribution of OT before and after apixaban treatment. (B) Distribution of LT before and after apixaban treatment. Apixaban significantly prolonged OT as evidenced by rightward shift (reduction in platelet reactivity). LT was significantly reduced as evidenced by leftward shift (representing faster lysis).



**Figure 2. Effect of apixaban on lysis time according to baseline LT**

The effect of apixaban on LT was particularly marked in patients with longest baseline LT.

\* p =0.040, \*\* p=0.018

